Through the combined expertise of basic, translational and clinical researchers, West Cancer Center’s Disease State Programs provide forums for innovative collaboration and result-oriented discussion in order to develop more effective therapies and a deeper multidisciplinary understanding of these and other diseases. With physicians and researchers from a variety of specialties and backgrounds, our initial Disease State Programs – Melanoma, Ovarian and Breast – provide successful models for the further development of these multidisciplinary groups.
Melanoma Research Group
Melanoma, the most deadly form of skin cancer, is commonly seen and treated disease type at West Cancer Center. West Cancer Center is also home to the nation’s premier experts in ocular (eye) melanoma, where almost 10% of all ocular (eye) melanoma cases diagnosed in the United States is seen and treated here. The Melanoma Research Group is comprised of basic, translational and clinical researchers with a variety of different specialties and focuses on the treatment of both cutaneous and ocular melanoma. With a particular interest in immunotherapy, the group includes physicians and researchers with specialties in Dermatology, Surgical Oncology, Ophthalmology, Radiation Oncology, Pathology and Medical Oncology.
Ovarian Cancer Research Group
The Ovarian Cancer Research Group’s goal is to fight ovarian cancer by developing new therapies and biomarkers. Ovarian cancer is one of the most deadly and least understood cancers. The team tasked with taking on this challenge includes basic scientists with expertise in drug discovery, experts in disease modeling, and both early and late-phase clinical researchers, as well as experts in observational and database research.
Breast Cancer Research Group
Breast cancer remains one of the most common and potentially deadly diseases at both the local and national level. At West Cancer Center, there was a 20% increase in new breast cancer cases year over year. The Breast Cancer Research Group is committed to improving both local and national outcomes in breast cancer. The group is heavily focused on both development and testing of novel therapeutics, health care disparities research and community outcomes. West Cancer Center is home to some of the most renowned experts in the field of breast cancer care and research, and continues to direct this collaborative focus to ensure not only the development of new therapeutics, but also the appropriate programmatic solutions to increase access to these new therapies throughout the community.